Using the intravesical delivery route to target the kidney
Abstract
Despite advances in drug delivery technologies, there is still an unmet demand for noninvasive kidney-targeted drug delivery systems that enhance therapeutic efficacy while minimizing systemic side effects. In the present study, we conducted a proof-of-concept study to evaluate the feasibility and effectiveness of intravesical delivery as a kidney-targeting strategy in mice. We demonstrated that intravesical infusion could retrogradely deliver molecules with a size up to 500 kDa to both the medulla and cortex of the kidney. In particular, empagliflozin, an antagonist of sodium-glucose cotransporter 2 (SGLT2), could effectively target the uppermost segment of the renal tubular system, that is, the proximal tubules, when administered via the intravesical route, thereby promoting glucose excretion. In an orthotopic renal carcinoma model, intravesical delivery of a chemotherapeutic agent achieved superior tumor suppression with markedly reduced adverse effects on extrarenal organs, compared with systemic administration at an equivalent dose. This improvement was attributed to a higher renal drug concentration and substantially lower systemic exposure achieved by intravesical delivery, demonstrating its kidney-targeting specificity. Thus, these findings indicated that the intravesical delivery route offers a promising strategy for kidney-targeted therapy and related translational research.NEW & NOTEWORTHY Intravesical infusion is valid for retrograde delivery of molecules up to…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.